Engineering enhanced CAR T-cells for improved cancer therapy

Chimeric antigen receptor (CAR) T-cell therapies have evolved from a research tool to a paradigm-shifting therapy with impressive responses in B cell malignancies. This review summarizes the current state of the CAR T-cell field, focusing on CD19- and B cell maturation antigen-directed CAR T-cells,...

Descripción completa

Detalles Bibliográficos
Autores principales: Milone, Michael C., Xu, Jie, Chen, Sai-Juan, Collins, McKensie A., Zhou, Jiafeng, Powell, Daniel J., Melenhorst, J. Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412433/
https://www.ncbi.nlm.nih.gov/pubmed/34485921
http://dx.doi.org/10.1038/s43018-021-00241-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412433/
https://www.ncbi.nlm.nih.gov/pubmed/34485921
http://dx.doi.org/10.1038/s43018-021-00241-5

Ejemplares similares